PDA Journal of GMP and Validation in Japan
Online ISSN : 1881-1728
Print ISSN : 1344-4891
ISSN-L : 1344-4891
Review
Points to Consider in Continuous Manufacturing of Biotechnological Products
Shinichi OKUDAIRAKyoko SAKURAIHiroshi TAKEDAYoshihiro MATSUDATetsuhito TAKARADAKohei KONDOMasabumi TAKAHASHIRyusei ISHIIKazuhisa UCHIDAIn EUI LEEKazuyo WADAYuki KOBAYASHIRie SHIMIZUYasubumi KATOHideki KURASHIMAKatsuhiro HATAYAMAToyoo OHDAYusuke TORIKAIKinya KARIYAJiro TSUKAMOTOHiroya OKURANaoto WATANABEKastushi MURAINaohito HARIGANEYARyutaro HIRASAWATomoko HONGOKazunobu OYAMAYoshiyuki TOKIEDAYasumasa OTAMizuyo SHIBATAHideki SHINONAGAYoichiro SHIBAYoshiaki SHIMIZUTakeshi YOSHINOTakayuki HORIUCHIYoshimitsu ISHIKAWASeigo OETadayoshi KAWASAKIHiroko SHIBATAMasashi HYUGAShinya HONDAShuichi YAMAMOTOSei MURAKAMITakeshi OMASAAkiko ISHII-WATABE
Author information
JOURNAL FREE ACCESS

2021 Volume 23 Issue 1 Pages 13-22

Details
Abstract

Continuous manufacturing is a manufacturing method in which raw materials are entered continuously in the manufacturing process throughout the duration of the process, and products are produced continuously through the manufacturing. Continuous manufacturing is applicable in various ways: Where all the stages of manufacturing process are continuous, from charging raw materials to discharging final products; and where only certain stages of the manufacturing process are continuous. With its continuous process operation, continuous manufacturing will be expected to maintain production efficiency irrespective of the equipment scale. By adjusting such as the continuous operating time in the process, continuous manufacturing can cater for a wide range of batch size. Therefore the same manufacturing equipment can be used from the developmental phase to the commercial phase. Continuous manufacturing is considered an efficient manufacturing technology, and considered to be one of major manufacturing technology in pharmaceutical production. Number of guidelines, however, published by regulatory agencies regarding continuous manufacturing is limited. There is no guideline by regulatory agencies specific to continuous manufacturing of biotechnological products. In this paper, we described points to consider when designing control strategy of continuous manufacturing of biotechnological products.

Content from these authors
© 2021 Parenteral Drug Association Japan Chapter
Previous article
feedback
Top